Vergoeding 2018-2022 voor ATC-subgroep L04AA : Selectieve immunosuppressiva
- Raming voor de totale Zvw-populatie
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| L04AA06 Mycofenolzuur (Cellcept ®) | 10.950.600 | 11.741.300 | 11.758.700 | 9.562.600 | 9.724.800 |
| L04AA10 Sirolimus (Rapamune ®) | 1.458.200 | 1.487.500 | 1.456.900 | 1.472.000 | 1.702.300 |
| L04AA13 Leflunomide (Arava ®) | 2.039.400 | 2.336.100 | 1.081.900 | 1.290.400 | 1.109.800 |
| L04AA18 Everolimus (Certican ®) | 4.946.800 | 5.274.100 | 4.997.900 | 4.843.000 | 5.508.700 |
| L04AA27 Fingolimod (Gilenya ®) | 27.140.800 | 27.466.100 | 25.303.800 | 25.289.700 | 23.853.100 |
| L04AA31 Teriflunomide (Aubagio ®) | 12.681.800 | 14.052.400 | 15.093.400 | 15.710.200 | 16.279.900 |
| L04AA38 Ozanimod (Zeposia ®) | . | . | 1.441 | 1.240.900 | 4.766.000 |
| L04AA40 Cladribine (Mavenclad ®) | 2.290.500 | 4.653.000 | 3.939.500 | 5.276.500 | 10.281.400 |
| L04AA42 Siponimod (Mayzent ®) | . | . | . | 1.364.100 | 3.406.600 |
| L04AA50 Ponesimod (Ponvory ®) | . | . | . | 157 | 494.330 |
| L04AA52 Ofatumumab (Kesimpta ®) | . | . | . | . | 1.525.100 |
| Totaal | 61.508.100 | 67.010.500 | 63.633.541 | 66.049.557 | 78.652.030 |